GlaxoSmithKline (GSK) → Stock, financial statements


Dividends News
  • GSK Ticker
  • 🇺🇸 NYSE, 🇬🇧 LSE Exchange
  • Employees
62 rated
comming soon
comming soon
comming soon
comming soon
comming soon
comming soon
comming soon
comming soon
comming soon

Financial statements — GlaxoSmithKline

The information is not 100% up-to-date. There may be errors or missing information. Some information is often missing, and, although there are almost no errors, I can't rule them out. Right now, I'm looking for a supplier of high-quality information, but so far what I'm finding is expensive (about $2000 a year). You can help my project here.
20 ← 16 2020 2019 2018 2017 2016
Total Revenue
46B 44B 39B 41B 34B
Cost Of Revenue
16B 16B 13B 14B 11B
Gross Profit
31B 29B 26B 27B 23B
Research and Development
6.9B 6B 4.9B 6B 4.5B
Selling General and Admin
16B 15B 13B 13B 12B
Operating Expense
39B 37B 31B 33B 27B
Operating Income
8B 7.8B 8.6B 7.7B 6.9B
Other Income Expense Net
430M 1.4B 380M 480M 490M
8.4B 9.2B 9B 8.2B 7.4B
Interest Income
1.1B 1B 760M 0 900M
Pretax Income
9.5B 8.2B 6.1B 4.7B 2.4B
Income Tax
790M 1.2B 960M 1.8B 1.1B
Minority Interest
870M 820M 540M 860M 180M
Net Income
7.8B 6.1B 4.6B 2.1B 1.1B
Net Income Basic
7.8B 6.1B 4.6B 2.1B 1.1B
20 ← 16 2020 2019 2018 2017 2016
Current cash
8.7B 6.3B 5B 5.3B 6.1B
Short term investments
1.1B 3.1B 2.1B 2.2B 2.2B
9.5B 7.2B 6.6B 6.3B 5.7B
8.2B 7.8B 6.9B 7.5B 6.3B
Other current assets
1.1B 3.1B 2.1B 2.2B 2.2B
Current assets
28B 26B 21B 21B 21B
Long term investments
82B 79B 52B 54B 52B
Property plant equipment
14B 14B 14B 15B 13B
14B 14B 7.3B 7.7B 7.3B
Intangible assets
41B 41B 22B 24B 23B
Other assets
2.6B 2.7B 2.1B 1.9B 1.5B
Total assets
110B 100B 74B 76B 73B
Accounts payable
5.9B 5.4B 4.6B 4.7B 4.4B
Current long term debt
5.1B 9.1B 7.4B 3.8B 5.1B
Other current liabilities
19B 17B 17B 27B 14B
Total current liabilities
30B 32B 29B 36B 23B
Long term debt
32B 31B 26B 19B 18B
Other liabilities
14B 13B 13B 14B 23B
Minority Interest
8.5B 9.1B -870M 4.8B 4.7B
Total Liabilities
90B 90B 68B 76B 71B
Common stock
2.5B 2.5B 2.5B 2.4B 2.4B
Retained earning
9.2B 5.9B -2.7B -8.7B -6.6B
Treasury stock
0 0 0 0 0
Capital surplus
Shareholder equity
20B 15B 5.5B -91M 1.4B
Net tangible assets
-35B -39B -24B -31B -29B
20 ← 16 2020 2019 2018 2017 2016
Net Income
7.8B 6.1B 4.6B 2.1B 1.1B
3.2B 3.1B 2.4B 2.6B 2.2B
Changes in receivables
2.3B 630M 290M 610M -2.6B
Changes in inventories
370M 850M -520M 1.2B -710M
Cash change
2.4B 1.3B -230M -870M -2.6B
Cash flow
12B 11B 11B 9.3B 8B
Capital expenditures
-3.1B -2.8B -2.3B -3B -2.9B
Investing activity other
Total investing cash flows
2.9B -7B -2B -1.9B -1.6B
Dividends paid
Net borrowings
27B 31B 26B 15B 15B
Other financing cash flows
Cash flow financing
-14B -2.4B -8.1B 8.6B -7.9B
Exchange rate effect

GlaxoSmithKline Plc is a global healthcare company which engages in researching, developing and manufacturing of pharmaceutical medicines, vaccines and consumer healthcare products. It operates through the following four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare. The Pharmaceuticals segment researches, develops and makes available medicines that treat a variety of serious and chronic diseases. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza and bacterial meningitis. The Consumer Healthcare segment markets a range of consumer health products based on scientific innovation. The company was founded in 1715 and is headquartered in Brentford, the United Kingdom.